Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
DBV:EPA
DBV Technologies SA
€3.40
+1.80%
(+0.060) 1D
Apr 24, 5:36:16 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for DBV...
Open
€3.34
High
€3.41
Low
€3.30
Mkt. cap
929.56M
Avg. vol.
1.11M
Volume
489.67K
52-wk high
€4.50
52-wk low
€1.30
EPS
-€0.90
Shares outstanding
278.35M
No. of employees
125
News stories
From sources across the web
Profile
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
About DBV Technologies SA
CEO-
Employees125
FoundedMar 29, 2002
Headquarters-
SectorBiotechnology
Websitedbv-technologies.com
Last report
Mar 27, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-0.20/ (-0.19 est.)EUR
-5.73%miss
Revenue / Estimate
528.00K/ (1.06M est.)EUR
-50.09%miss
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
753.00K
1.46M
2.77M
645.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21.48M
33.69M
28.62M
32.89M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.89M
8.88M
8.44M
12.80M
Operating expense
27.37M
42.58M
37.05M
45.70M
Total operating expenses
27.37M
42.58M
37.05M
45.70M
Operating income
-26.62M
-41.11M
-34.28M
-45.05M
Other non operating income
-
-
1.00K
-1.00K
EBT including unusual items
-27.08M
-41.76M
-33.16M
-44.46M
EBT excluding unusual items
-27.08M
-41.76M
-33.16M
-44.46M
Income tax expense
-
117.00K
-
374.00K
Effective tax rate
-
-0.28%
-
-0.84%
Other operating expenses
-
-
-
-
Net income
-27.08M
-41.88M
-33.16M
-44.83M
Net profit margin
-3,596.15%
-2,858.36%
-1,195.53%
-6,950.23%
Earnings per share
-
-
-
-
Interest and investment income
-
-
1.11M
597.00K
Interest expense
-461.00K
-648.00K
-
-
Net interest expenses
-461.00K
-648.00K
1.11M
597.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.67M
-40.35M
-33.49M
-44.36M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer